tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
MapLight Therapeutics reports Q3 EPS ($37.18) vs ($25.08) last year
PremiumThe FlyMapLight Therapeutics reports Q3 EPS ($37.18) vs ($25.08) last year
22d ago
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts
Premium
Ratings
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts
22d ago
ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
Premium
The Fly
ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
22d ago
MapLight Therapeutics initiated with a Buy at Jefferies
PremiumThe FlyMapLight Therapeutics initiated with a Buy at Jefferies
1M ago
MapLight Therapeutics initiated with an Overweight at Morgan Stanley
Premium
The Fly
MapLight Therapeutics initiated with an Overweight at Morgan Stanley
1M ago
Premium
Company Announcements
MapLight Therapeutics Closes Successful IPO and Private Placement
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100